Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.
Breast cancer, with its myriad subtypes, has long eluded a uniform treatment strategy. The disease's molecular complexity has rendered traditional, blanket treatments insufficient, particularly for ...
SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, ...
According to the World Cancer Research Fund, more than 100,000 men are newly diagnosed with prostate cancer annually in Japan, and a portion of those patients will be diagnosed with or later progress ...
The stiffness of tumor tissue plays a role in how cancer spreads. Furthermore, stiff tumor tissue leaves traces in the ...
Some of the earliest warning signs of breast cancer risk may be hidden deep within the molecular makeup of breast tissue—long ...
SALT LAKE CITY, March 17, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and ...
Purdue University researchers have identified a molecular mechanism that naturally slows the uncontrolled cell division seen in many cancers. Using atomic-level imaging, they mapped how the protein ...
New research provides compelling evidence that Barrett’s esophagus underlies all cases of esophageal adenocarcinoma, even ...
Cancer drugs are designed to shut tumors down. But sometimes, in the very act of attacking a tumor, treatment can also help a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results